Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure

European Journal of Heart Failure

Volumn 5, Issue 2, 2003, Pages 171-174

  Chin, Bernard S P ^a   Langford, Nigel J ^b   Nuttall, Sarah L ^b   Gibbs, Christopher R ^a   Blann, Andrew D ^a   Lip, Gregory Y H ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

ACE inhibitors; Beta blockers; Congestive heart failure; Endothelial damage dysfunction; Oxidative stress

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; NITRATE; STATINE DERIVATIVE; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROMATOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CATECHOLAMINE BLOOD LEVEL; CELL DAMAGE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BISOPROLOL; BLOOD PRESSURE; CARBAZOLES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; LIPID PEROXIDES; LISINOPRIL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROPANOLAMINES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 0037348838     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00251-9     Document Type: Article

References (19)

1. Sies H. Strategies of antioxidant defence. Eur J Biochem 1993;215:213-9.
2. Gutteridge JMC. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995;41:1819-28.
3. Keith M, Geranmayegan M, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhay KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-6.
4. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 1997;12:259-64.
5. Kaul N, Siveski-Iliskovic N, Hill M, et al. Free radicals and the heart. J Pharmacol Toxicol Methods 1993;30:55-67.
6. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systemic overview of randomised controlled trials. Eur Heart J 1997;18:560-5.
7. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effects of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Circulation 1990;82:473-83.
8. Feuerstein G, Yue TL, Ruffolo RR. Novel mechanism in the treatment of heart failure: inhibition of oxygen free radicals in apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41(Suppl 1):17-24.
9. Gibbs C, Blann AD, Watson RDS, Lip GYH. Abnormalities of haemorheological, endothelial and platelet function, in patients with chronic heart failure in sinus rhythm: effects of ACE inhibition and beta-blocker therapy. Circulation 2001;103:1746-51.
10. Nourooz-Zadeh J, Tajaddini-Samardi J, Wolff SP. Measurement of plasma hydroperoxide concentrations by the ferrous-oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 1994;220:403-9.
11. Whitehead TP, Thorpe GHG, Maxwell SRJ. Enhanced chemiluminescent assay for antioxidantr capacity in biological fluids. Anal Chim Acta 1992;266:265-77.
12. Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Rads Biol Med 1999;27:1173-81.
13. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991.
14. Minitab version B, Minitab Statistical software Inc., Progress Drive, State College, Philidelphia, PA, USA.
15. Child RB, Wilkinson DM, Fallowfield JL, Donnelly AE. Elevated serum antioxidant capacity and plasma malondialdehyde concentration in simulated half-marathon run. Med Sci Sports Exercise 1998;30:1603-7.
16. Mancini GB. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med 2000;2:144-61.
17. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial cell damage in essential hypertension. J Hum Hypertension 1993;7:107-11.
18. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.
19. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 25 May 1999;99(20):2645-51.